EID and Viral Load Product and Site Selection Tool

Slides:



Advertisements
Similar presentations
Group III: Demand Forecasting
Advertisements

The Roadmap to Successful Xpert Implementation - 37 steps -
The Future of HIV Diagnostics: Market Trends for CD4 and VL Testing Decade of Diagnostics Satellite Kuala Lumpur July 2, 2013.
Scaling up Early Infant HIV Diagnosis (EID) in Karamoja Health Nutrition HIV coordination meeting 9 th December 2009.
Introduction to PEPFAR 3.0 and DATIM.
Introduction to Laboratory Quantification Lab TWG Jason Williams, Principal Laboratory Advisor, SCMS February 20-21, 2013.
The Current Pipeline for Point-of-Care Virologic Testing for HIV/AIDS Scaling up Virologic Diagnostic HIV Testing in Infants and Rationalizing Decentralization.
Washington D.C., USA, July 2012www.aids2012.org A National Program Manager’s Perspective on HIV/TB Integration Dr Owen Mugurungi Director – AIDS.
Cost Comparison of Point-Of-Care and Conventional CD4 Testing in Resource-Limited Settings Ilesh V. Jani Instituto Nacional de Saúde Maputo, Mozambique.
Introducing New POC Devices in National Programs: Focus on Early Infant Diagnosis July 2014.
Developing Guiding Principles for ICT in Education Policy
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
PAVEMENT MANAGEMENT SYSTEMS OVERVIEW Lecture 2. n Provide a historical perspective of the evolution of PMS over the last 20 years n Describe the basic.
Instrument and Test Forecasting: Considerations in Implementation of New Diagnostics Jason Williams Principal Laboratory Advisor.
Accelerating access to innovative point of care HIV diagnostics Decade of Diagnostics Satellite Session Washington, DC July 22, 2012.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
IIIIIIIIIIIIIIIIII Point of care testing (POCT) Dr K.A.C.Wickramaratne.
Wilbert Bannenberg SARPAM
OPERATING ROOM DASHBOARD Virginia Chard, RN, BSN, CNOR
September 2009 Guide to Producing Campaign to End Pediatric Aids (CEPA) National Advocacy Action Plans (NAAPs)
1 Module OVERVIEW OF EXTERNAL QUALITY ASSESSMENT.
Creating a Shared Vision Model. What is a Shared Vision Model? A “Shared Vision” model is a collective view of a water resources system developed by managers.
Existing Challenges – POC Introduction Lab Technical Working Group Jason Williams, Principal Laboratory Advisor, SCMS January 20-21, 2013.
Ilesh V. Jani, MD PhD Instituto Nacional de Saúde Maputo, Mozambique.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
Impact of Early Infant Diagnostic (EID) Testing for HIV Exposed Infants in Namibia Dr. Ndapewa Hamunime (MOHSS) Dr. Andreas Shiningavamwe (NIP) Republic.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
Chapter 10 Sales and Operations Planning (Aggregate Planning)
LFA PSM expert workshop January 2014 Strategies for supporting the rational scale-up of laboratory monitoring of HIV.
Assessing Logistics System Supply Chain Management 1.
Clinic systems should be adapted to maximize the benefits of point-of-care CD4 technology Point-of-Care CD4 Systems Integration in Uganda December 2011.
Project: EaP countries cooperation for promoting quality assurance in higher education Maria Stratan European Institute for Political Studies of Moldova.
UNITAID/EGPAF Project to Optimize Early Infant HIV Diagnosis through the Introduction of Point of Care Testing Optimization of EID networks through introduction.
CDC and support for Point of Care Testing Accreditation Muthoni Junghae CDC-Kenya LAUNCH OFF POINT OF CARE TESTING ACCREDITATION PROGRAM PANAFRIC HOTEL-18TH.
Community Score Card as a social accountability Approach Methodology and Applications March 2015.
Early Infant Diagnosis - Impact of the point-of-care testing approach with Alere(tm) q HIV-1/2 Detect 9th IAS Conférence on HIV Science (IAS 2017)
Stages of Research and Development
IAS Satellite Session, 25 July 2017
Emphasis programmatic / civil society and lab must not act in silos – need to come together for effective scale up Programmatic and Laboratory Must Speak.
Logic Models How to Integrate Data Collection into your Everyday Work.
Procurement Development Programs
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
Comparing Conventional to Point-of-Care (POC) Early Infant Diagnosis (EID): Pre and post intervention data from a multi-country evaluation. Flavia Bianchi,
Overview of recommended indicators for routine monitoring of iCCM
One Approach to Bundled Payments
Integrated Testing on the GeneXpert
iCCM Recommended Indicators
Point-of-Care EID and VL Products: What’s in the Pipeline?
Wilbert Bannenberg SARPAM
Using data to monitor POC performance
Facilitating development and adaptation of the right tools
Zimbabwe’s shift towards treat all: national country context
Development of the detailed Nutrition Response Plan
Supply and demand: improving the open ag funding data landscape
Integrated Testing on the GeneXpert
Country Progress Report Cambodia
CEO Owner Update June 12, 2018.
Find and Treat All Missing Persons with TB
Project Ideation Agile Down-to-Earth © 2016.
VL DIAGNOSTIC TESTING SERVICE DELIVERY IN KENYA
Access to HIV/AIDS Medicines The 3x5 strategy
AIDS TO A HIGH CATARACT SURGICAL RATE
Stevenson 5 Capacity Planning.
Ministry of Health, Kenya
Role of KMLTTB in HIV POC implementation
KEY INITIATIVE Financial Data and Analytics
Multi-disease diagnostic integration
Illustrative Cluster Detection and Response Strategy
Overview of the POC EID Training Toolkit
Data Management for POC EID
Presentation transcript:

EID and Viral Load Product and Site Selection Tool May 2015

Background: Why is a product selection process necessary? Comprehensive product information Historically, in the diagnostics sector, decision-makers have lacked sufficient information to make informed product selection decisions Suppliers provide Ministries of Health (MOHs) with extensive marketing materials, but they lack comprehensive and unbiased information to pick the products that are most appropriate for their countries Public procurement principles Public funding requires that public procurement principles be observed in the procurement of commodities. MOHs have an obligation to demonstrate that a rational and transparent process has been followed to select products for procurement. There is a role to play for neutral 3rd parties to facilitate the development of a rational and transparent product selection process.

Key Principles of Product and Site Selection It should be MOH-led and involve all key stakeholders to drive consensus It should be rational, transparent, and well-documented It should be driven by the country’s unique diagnostic testing priorities, including such factors as: Patient volumes Clinical need (i.e., potential need for emergency EID testing in hospitals) Access challenges (low-volume sites with long turnaround times and/or sites that are located far from centralized testing labs) Cost efficiency 4. It should be an iterative process

Product and site selection tool are just part of a broader process Select products for evaluation Convene TWG Review product information Product selection Conduct evaluations Select products for Pilot/scale-up Note: Countries are increasingly working to harmonize and share evaluation results to minimize duplication. Convene TWG Review evaluation results Product selection Site selection tool Pilot/Scale-up

The product and site selection tool and accompanying guidance can be used to facilitate stakeholder discussions Understand current testing landscape Understand the current gaps in testing coverage in the country: What segments have the poorest access to testing? At what level of the health system do most patients seek care? Which segments of the health system would be best served by POC? Determine key criteria Determine the most important ~5 – 10 criteria when selecting POC products Discuss how these criteria should be weighted against each other in each segment Determine balance between patient numbers, access, and price to be used in site selection Review product pipeline and assign scores to products Review all available information for each product Assign scores for each of the products for the criteria determined in step 2 Select POC products and sites Review scores for each product in the various segments Hold discussions across all stakeholders to consider scores and other relevant factors Select products for evaluation and/or scale-up and match to appropriate sites Repeat process periodically to include new products and new information

EID and VL Site and Product Selection Tool Overview (1 of 5) Goal: Help countries determine optimal deployment of POC and conventional equipment at a site level to maximize patient impact while maintaining cost efficiency 1 Define country and site-level information Enter details regarding country guidelines, existing equipment, lab operations, sample transportation, costs, and site-level patient data, including but not limited to: ART patients PMTCT patients OR historical EID test numbers Existing access to testing (EID or VL) Distance from lab or turnaround time in days Presence of pediatric or nutrition ward 2 Assign site selection criteria Weight most important criteria for site selection, including minimizing cost, improving on-site access to testing, or maximizing patient coverage Choose maximum number of devices to be deployed per site

EID and VL Site and Product Selection Tool Overview (2 of 5) 3 Assess existing coverage through conventional systems and role of POC Outputs of site-level data used to define access to on-site testing User can test various scenarios shifting balance from conventional to POC at national level to determine potential patient and cost impact This will help inform the overall balance between POC and conventional testing in country

EID and VL Site and Product Selection Tool Overview (3 of 5) 4 Determine key criteria for new product selection Identify all the factors that should be considered when selecting new product Identify percentage weights to be given to each criteria Performance Criteria >0 and <=5 >5 and <=10 >10 and <=20 >20 Tests Offered (EID or VL)   5% 10% Quantitative/Semi-Quantitative Device/Device-Free Throughput 15% 25% Power Source 20% Connectivity Device Cost Reagent Cost Ease of Use After-Sale Support 5 Review product pipeline and assign scores to products 6 Select new products to deploy

EID and VL Site and Product Selection Tool Overview (4 of 5) 7 Score and select sites and assign products Sort sites to rank from highest to lowest based on EID, VL, or both Select which sites will be chosen for new product deployment Designate product for all chosen sites

EID and VL Site and Product Selection Tool Overview (5 of 5) 8 Review outputs and adjust as necessary Review model outputs, including: Distribution of on-site access to testing by facility size List of sites and devices selected Required budget Average cost per test Public health impact Adjust model outputs based on findings

Introducing New POC Devices in Zimbabwe: Focus on Early Infant Diagnosis May 2016

Agenda Zimbabwe POC Implementation Guidelines Case Study: POC Product Selection Case Study: POC Site Selection

Implementation guidelines: Driven by country’s overall plan The POC Guidelines Development Task Force was formed by Ministry of Health and Child Care Department of Laboratory Services (MOHCC-DLS) to draft POC Testing Guidelines; Actively participated by key partners: MLSCZ, ZINQAP, CHAI, UNICEF, EGPAF, JSI ,MSF, ZNA, AFZ, NBTS In 2015, the National POC Testing Guidelines was approved by the MOHCC Permanent Secretary The POC Testing Guidelines : Define the strategy for POC, including guidelines and criteria for selecting products and sites for deployment; Include a roadmap for product-agnostic systems for training, quality assurance, supply chain and distribution, service and maintenance, data management, and M&E; Per the POC Testing Guidelines Facilitation of the product selection process has included both quantitative scoring and qualitative discussion among MOHCC-led TWGs and specific programs such as PMTCT and HIV/TB. Please note that the POC guidelines apply to all POC and near POC testing ( HIV screening, CD4, EID, VL, HCV, etc)

Agenda Zimbabwe POC Implementation Guidelines Case Study: POC Product Selection Case Study: POC Site Selection

Key Principles of Product Selection per POC Testing Guidelines It must be led by the MOHCC-DLS The process should involve all key stakeholders to drive consensus Rational and transparent criteria will be used to identify the most suitable products The process should be well documented demonstrating the rationale for the selection of suitable products The tools should be flexible so that Zimbabwe can customize the process according to its needs The process must be iterative as the laboratory network and available technologies evolve Add comment on how the tool help improve product selection process in the past and how similar tool will help improve unbiased product selection for EID and VL

Product Selection Case Study: Zimbabwe POC EID Attendance: National Microbiology Reference laboratory (NMRL/MOHCC), EGPAF, MSF, UNICEF, CHAI 1 Understand current testing landscape for EID CHAI presented on the current access to on-site testing in Zimbabwe The group focused on: Largest segments where pediatric patients seek HIV care and treatment; Segments with poor access to on-site testing and where there is availability to off-site testing; 2 Determine key criteria for POC EID selection The group identified all the factors that should be considered when selecting POC EID Devices The top 11 criteria were determined The group discussed the percentage weights to be given to each criteria:

Product Selection Case Study: Zimbabwe POC EID Explain briefly why some of the criteria where weighted as they are. Please note that the higher the percentage, the more important it is.

Product Selection Case Study: Zimbabwe POC EID 3 Review product pipeline and assign scores to products for POC EID CHAI presented the available information on each of the products The group discussed features and advantages of each of the products The group determined scores for each of the products against each of the 11 criteria Please note that the higher the score, the better the product performs. The score are as objective as possible based on experience with the device and information shared by the manufacturers. *Performance Criteria scored from a low of 1 to a high of 5

Product Selection Case Study: Zimbabwe POC EID 4 Select POC EID products The tool provides scores for each product in each segment The group discussed the resulting scores: Which products scored best in each segment? Were the results expected? If not, what was missed? What additional data is required to improve the accuracy of the scores? Are the differences between various top scoring products significant? How many products are needed in the country? The group, led by MOHCC, documented its selections with formal meeting minutes The group made plans to repeat this process in the future When presenting, briefly elaborate what the group discussed regarding resulting scores of product selection. Product 1- Alere q; Product 2 –Cepheid GeneXpert; Product 3- Samba II; Product 4- Omni

Agenda Zimbabwe POC Implementation Guidelines Case Study: POC Product Selection Case Study: POC Site Selection

Key Principles of Site Selection per POC Testing Guidelines It must be led by the MOHCC-DLS The process should involve all key stakeholders to drive consensus Should be driven by the country’s unique diagnostic testing priorities, including such factors as: Patient volumes Access challenges (low-volume sites with long turnaround times and/or sites that are located far from centralized testing labs) Alternative entry points for testing (i.e., pediatric wards & nutrition rehabilitation unit for EID) The process should be well documented demonstrating the rationale for the selection of suitable sites

Site Selection: Zimbabwe mapped all sites by key criteria and selected sites most appropriate for POC diagnostics deployment based priorities Key criteria Patient volumes at each site: shall consider actual/expected volume based on number patients requiring the tests Distance from a regional lab: accessibility of the testing site to the nearest conventional lab for back up, monitoring and quality assurance ART coverage rate : high number of ART patients at the facility requiring VL testing for care monitoring HIV prevalence: intend to consider sites or entry and testing points with high HIV burden for high patient impact Road quality: will consider hard to reach sites due to difficult terrain/ impassable road to provide onsite access to testing Country Priorities Prioritizing more remote facility within each province Patient volumes: moderate/low volume sites with long turnaround time Access to labs: sites that are located far from centralized testing labs and no reliable sample transport mechanism

There is a sweet spot for sites where laboratory based and POC testing make economic sense based on throughput, cost and complexity Highest volume sites Lowest volume sites Suited to laboratory based Suited to POC Actual share of the market will depend on: Country preference Leverage current laboratory based platforms? Price points for device/reagents Cost of POC test vs laboratory based + sample transport Throughput of POC/near-POC # of machines required to meet patient need vs. burden on health workers Guidelines on DBS Without DBS, laboratory based may not be able to reach peripheral sites

Market Segmentation by facility level and EID sample volumes Site-level data can be used to identify gaps in testing coverage and target opportunities to use POC to maximize linkage to treatment Market Segmentation by facility level and EID sample volumes Test Need/day Provincial Hospitals District Hospitals Health Centers TOTAL >10 Tests per Day 0% 5% 5-10 Tests per Day 2-5 Tests per Day 1% 8% 14% 1-2 Tests per Day 0.5% 13% 21% 0-1 Tests per Day 15% 40% 55% 1.5% 46% 53% 100% Most sites test only 0-1 patients per day. Some combination of district hospitals and health centers with greatest unmet need and poor access may be the best use cases for EID POC. Note: This is sample data from an analysis of 2015 Zimbabwe EID Market Segmentation Analysis

Next Steps Final note, once product and sites were selected the next steps would be to review the budget, evaluate the impact of site selection on testing coverage and review the final list of sites and devices selected for POC deployment Present the outcome of the product and site selection to the TWGs Evaluate/Review the impact of site selection on testing coverage Review the final list of sites and devices selected for POC pilot deployment and eventual scale up Develop the deployment plan and execute product deployment to selected sites